136 related articles for article (PubMed ID: 12105315)
1. Preference-based quality-of-life in patients with Parkinson's disease.
Siderowf A; Ravina B; Glick HA
Neurology; 2002 Jul; 59(1):103-8. PubMed ID: 12105315
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the construct validity and responsiveness of preference-based quality of life measures in people with Parkinson's: a systematic review.
Xin Y; McIntosh E
Qual Life Res; 2017 Jan; 26(1):1-23. PubMed ID: 27778141
[TBL] [Abstract][Full Text] [Related]
3. Health-related quality of life in Parkinson disease: correlation between Health Utilities Index III and Unified Parkinson's Disease Rating Scale (UPDRS) in U.S. male veterans.
Kleiner-Fisman G; Stern MB; Fisman DN
Health Qual Life Outcomes; 2010 Aug; 8():91. PubMed ID: 20799993
[TBL] [Abstract][Full Text] [Related]
4. The EQ-5D--a generic quality of life measure-is a useful instrument to measure quality of life in patients with Parkinson's disease.
Schrag A; Selai C; Jahanshahi M; Quinn NP
J Neurol Neurosurg Psychiatry; 2000 Jul; 69(1):67-73. PubMed ID: 10864606
[TBL] [Abstract][Full Text] [Related]
5. Preference-based quality of life in patients with Alzheimer's disease.
Karlawish JH; Zbrozek A; Kinosian B; Gregory A; Ferguson A; Glick HA
Alzheimers Dement; 2008 May; 4(3):193-202. PubMed ID: 18631968
[TBL] [Abstract][Full Text] [Related]
6. How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population.
Schrag A; Jahanshahi M; Quinn N
Mov Disord; 2000 Nov; 15(6):1112-8. PubMed ID: 11104193
[TBL] [Abstract][Full Text] [Related]
7. Quality of life in a German cohort of Parkinson's patients assessed with three different measures.
Balzer-Geldsetzer M; Klotsche J; ; Dodel R; Riedel O
J Neurol; 2018 Nov; 265(11):2713-2722. PubMed ID: 30209651
[TBL] [Abstract][Full Text] [Related]
8. The Key Determinants to Quality of Life in Parkinson's Disease Patients: Results from the Parkinson's Disease Biomarker Program (PDBP).
He L; Lee EY; Sterling NW; Kong L; Lewis MM; Du G; Eslinger PJ; Huang X
J Parkinsons Dis; 2016 May; 6(3):523-32. PubMed ID: 27258700
[TBL] [Abstract][Full Text] [Related]
9. Utilities Estimated from PROMIS Scales for Cost-Effectiveness Analyses in Stroke.
Thompson NR; Lapin BR; Katzan IL
Med Decis Making; 2023 Aug; 43(6):704-718. PubMed ID: 37401739
[TBL] [Abstract][Full Text] [Related]
10. Validity of utility measures for women with pelvic organ prolapse.
Harvie HS; Lee DD; Andy UU; Shea JA; Arya LA
Am J Obstet Gynecol; 2018 Jan; 218(1):119.e1-119.e8. PubMed ID: 28988907
[TBL] [Abstract][Full Text] [Related]
11. The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis: a head-to-head comparison.
Oostenbrink R; A Moll HA; Essink-Bot ML
J Clin Epidemiol; 2002 Aug; 55(8):791-9. PubMed ID: 12384194
[TBL] [Abstract][Full Text] [Related]
12. Parkinson's disease with early motor complications: predicting EQ-5D- 3L utilities from PDQ-39 data in the EARLYSTIM trial.
Zahra M; Durand-Zaleski I; Górecki M; Walleser Autiero S; Barnett G; Schüpbach WMM
Health Qual Life Outcomes; 2020 Mar; 18(1):49. PubMed ID: 32122369
[TBL] [Abstract][Full Text] [Related]
13. Correlation of quality of life and functional outcome measures for cervical spondylotic myelopathy.
Lubelski D; Alvin MD; Nesterenko S; Sundar SJ; Thompson NR; Benzel EC; Mroz TE
J Neurosurg Spine; 2016 Mar; 24(3):483-9. PubMed ID: 26613280
[TBL] [Abstract][Full Text] [Related]
14. Functional outcome instruments used for cervical spondylotic myelopathy: interscale correlation and prediction of preference-based quality of life.
Whitmore RG; Ghogawala Z; Petrov D; Schwartz JS; Stein SC
Spine J; 2013 Aug; 13(8):902-7. PubMed ID: 23523443
[TBL] [Abstract][Full Text] [Related]
15. Caregivers' assessments of preference-based quality of life in Alzheimer's disease.
Karlawish JH; Zbrozek A; Kinosian B; Gregory A; Ferguson A; Low DV; Glick HA
Alzheimers Dement; 2008 May; 4(3):203-11. PubMed ID: 18631969
[TBL] [Abstract][Full Text] [Related]
16. Mapping the EQ-5D index by UPDRS and PDQ-8 in patients with Parkinson's disease.
Dams J; Klotsche J; Bornschein B; Reese JP; Balzer-Geldsetzer M; Winter Y; Schrag A; Siderowf A; Oertel WH; Deuschl G; Siebert U; Dodel R
Health Qual Life Outcomes; 2013 Mar; 11():35. PubMed ID: 23497005
[TBL] [Abstract][Full Text] [Related]
17. Which Questionnaire Should Be Used to Measure Quality-of-Life Utilities in Patients with Acute Leukemia? An Evaluation of the Validity and Interpretability of the EQ-5D-5L and Preference-Based Questionnaires Derived from the EORTC QLQ-C30.
van Dongen-Leunis A; Redekop WK; Uyl-de Groot CA
Value Health; 2016; 19(6):834-843. PubMed ID: 27712712
[TBL] [Abstract][Full Text] [Related]
18. Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson's disease.
Dodel R; Jönsson B; Reese JP; Winter Y; Martinez-Martin P; Holloway R; Sampaio C; Růžička E; Hawthorne G; Oertel W; Poewe W; Stebbins G; Rascol O; Goetz CG; Schrag A
Mov Disord; 2014 Feb; 29(2):169-76. PubMed ID: 23861335
[TBL] [Abstract][Full Text] [Related]
19. A comparison of preference assessment instruments used in a clinical trial: responses to the visual analog scale from the EuroQol EQ-5D and the Health Utilities Index.
Glick HA; Polsky D; Willke RJ; Schulman KA
Med Decis Making; 1999; 19(3):265-75. PubMed ID: 10424833
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the content validity of generic preference-based measures for use in Parkinson's disease.
Kuspinar A; Mate K; Lafontaine AL; Mayo N
Parkinsonism Relat Disord; 2019 May; 62():112-116. PubMed ID: 30685325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
